Recently, a new Myelofibrosis Transplant Scoring System (MTSS) was proposed to predict survival after HSCT on the basis of the following clinical and molecular variables: leukocytes >25 × 109/L, platelets <150 × 109/L, Karnofsky scale <90%, age >57 years, ASXL1 mutation (1 point each), JAK2-mutated or triple negative status (2 points), and mismatched unrelated donor (2 points) [27]. This evidence concerns the gene JAK2 and myelofibrosis.